GET DAILY SIGNALSTScan Therapeutics (TCRX): Reaching the $1.00 Target from $0.19 Would Mean a +426% Gain
Key Takeaways
- The central price target used here is $1.00, the arithmetic mean of the current post-restructuring analyst price targets, which have converged near $1 after steep cuts in September 2026.
- With TScan Therapeutics, Inc. (TCRX) trading near $0.19, reaching $1.00 would require a rise of roughly 426%, a very large move for a clinical-stage biotech.
- The stock's 1-year analyst consensus is a Hold, reflecting reduced conviction after the company paused its hematologic malignancies program to focus on its in vivo TCR-T pipeline for solid tumors.
- H.C. Wainwright cut its target to $1 (from $7) and downgraded to Neutral, while Wedbush cut to $1 (from $5) and moved to Hold, mirroring a broader retreat in sell-side expectations.
- The strongest supports are a simplified development focus and near-term clinical catalysts; the biggest risks are cash runway concerns, a going-concern warning, and Nasdaq minimum-bid delisting risk.
- Readers can follow the company's Major News and Today's Price Move, review the Forecast, and track upcoming Earnings on dedicated pages for this ticker.
- Explore Trending AI Robots to see how AI-driven tools are being used to monitor changing market conditions across thousands of stocks and ETFs.
Analyst Price Targets and Consensus View
TScan Therapeutics, Inc. (TCRX) is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Following a September 2026 restructuring that paused its hematologic malignancies program in favor of its in vivo TCR-T work in solid tumors, the sell-side view shifted sharply. H.C. Wainwright analyst Andres Maldonado downgraded the stock to Neutral from Buy and cut the target to $1 from $7, saying the restructuring "raises more questions than answers" about whether the company's cash runway can support its promised 2027 milestones. Around the same time, Wedbush cut its target to $1 from $5 and moved to Hold, while LifeSci Capital also downgraded to Hold.
Several data providers now report an average 12-month analyst target of $1.00, with the consensus rating at Hold. Because the recent revisions pulled targets down from a prior range of roughly $5 to $7, the current target range is narrow, clustering around $1.00. This is the arithmetic mean of the verified, current analyst targets, not a prediction that the stock will reach that level. The wide downward revision between 2025 and 2026 illustrates how quickly biotech price targets can change when clinical priorities and balance sheets shift. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The stock has traded around $0.19 in early November 2026, down more than 90% over the past year and sitting near the bottom of a 52-week range of roughly $0.17 to $1.47. At that price, moving to the $1.00 target would require a gain of approximately 426%, a very large move by any standard. Reaching the target would likely require both the successful execution of the in vivo TCR-T strategy and a meaningful improvement in investor confidence around funding and Nasdaq listing compliance. The path is not linear: it would depend on clinical data, financing, and a stabilization of the share price above the $1.00 minimum bid threshold the company currently falls short of.
What Could Support a Move Toward the Target
The company's narrowed focus on its in vivo TCR-T platform for solid tumors could, over time, sharpen the investment story and reduce cash burn relative to the prior multi-program approach. Positive early clinical data, new partnerships, or successful fundraising would address the two most pressing investor concerns: pipeline validity and balance-sheet durability. A completed reverse stock split, which shareholders will consider at a November 20, 2026 special meeting, could also lift the nominal share price back above $1.00 and restore Nasdaq compliance, removing a near-term overhang. Because the stock is highly volatile, even modest positive catalysts have historically produced outsized percentage moves in either direction.
What Could Prevent the Target From Being Reached
The principal risks are financing and solvency. The company has disclosed a going-concern warning and received a Nasdaq deficiency notice in August 2026 after trading below $1.00 for 30 consecutive days; it has until February 2027 to regain compliance. A reverse split may cure the listing problem but does not address the underlying cash runway, and the departure of senior executives, including the CFO and CMO, adds execution uncertainty. Dilutive financing, disappointing clinical results, or failure to secure capital could push the shares lower and make the $1.00 target, already a very large percentage move away, harder to justify.
Technical Levels and Market Structure
The $0.17–$0.18 area represents the recent 52-week low and is the most durable nearby support zone, while the $1.00 level serves both as a psychological round number and as the Nasdaq minimum-bid compliance threshold. Above that, prior highs near $1.47 mark the next significant resistance. The stock's long-term trend remains firmly negative, and any move toward $1.00 would first require the price to hold above the low and then clear multiple overhead levels created by the extended decline.
Time Horizon and What Investors Should Monitor
Analyst price targets for TCRX generally reflect a roughly 12-month research horizon, though the company has not published a formal horizon for the current $1.00 targets. Investors should watch the November 2026 special meeting on the reverse split, any financing or partnership announcements, updates on the in vivo TCR-T program, and quarterly cash position disclosures. Nasdaq compliance progress ahead of the February 2027 deadline, along with any analyst target or rating revisions, will be especially relevant to whether the $1.00 objective remains credible. From what I see, these milestones are worth tracking closely.
Final Assessment
The $1.00 target for TScan Therapeutics reflects the arithmetic mean of current analyst price targets that were sharply reduced after the September 2026 restructuring. From a price near $0.19, reaching that level would require an increase of about 426%, an exceptionally large move that hinges more on financing, Nasdaq compliance, and early-stage pipeline execution than on near-term fundamentals. Supporters point to a simplified strategic focus and potential clinical catalysts, while skeptics emphasize the going-concern warning, cash runway doubts, and delisting risk. There is no guarantee the stock will approach the target, and the wide gap between the current price and the target underscores both the upside that analysts' figures imply and the substantial uncertainty embedded in a clinical-stage biotech trading near its lows.
AI Daily Buy/Sell Signals
In my own research process, I have found Tickeron's AI Daily Buy/Sell Signals helpful for a volatile name like TCRX. These signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a highly volatile name like TCRX, these signals can help traders surface opportunities, keep tabs on shifting momentum, and spot emerging trends more efficiently than manual screening alone. Traders interested in a data-driven complement to fundamental research can explore these signals to monitor positions and identify changing conditions across the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TCRX sees its Stochastic Oscillator climbs out of oversold territory
On November 10, 2026, the Stochastic Oscillator for TCRX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 58 instances where the indicator left the oversold zone. In 49 of the 58 cases the stock moved higher in the following days. This puts the odds of a move higher at over 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TCRX's RSI Oscillator exited the oversold zone, 33 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +17.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where TCRX advanced for three days, in 188 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
TCRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TCRX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.185) is normal, around the industry mean (3.498). P/E Ratio (-0.209) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.046) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. TCRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement